Canadian government concludes CETA, which is welcomed by Rx&D
Canada’s Research-Based Pharmaceutical Companies (Rx&D) association applauds the government of Canada’s announcement regarding the successful conclusion of negotiations surrounding the Comprehensive Economic and Trade Agreement (CETA).
“This is an historic agreement for Canada and an essential step in strengthening Canada’s position on the international life sciences stage,” said Russell Williams, president of Rx&D. “A more level playing field in intellectual property protection can lead to more investment in the research and development of new medicines and vaccines here at home. It is a catalyst for innovation, and that’s good for Canada, but most importantly, it offers hope to Canadian patients and their families who rely upon the discovery of new and better medicines to help battle serious health challenges.”
The life sciences intellectual property improvements included in CETA are:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze